Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Autor: Edoardo Bertero, Linda W. van Laake, Petar M. Seferovic, Ewa A. Jankowska, Javid Moslehi, Frank Ruschitzka, Richard N. Kitsis, Johann Bauersachs, Jean-Sébastien Hulot, Ovidiu Chioncel, Patrycja Nowak-Sliwinska, Joseph Pierre Aboumsallem, Dirk Jäger, Rudolf A. de Boer, Peter van der Meer, Douglas B. Sawyer, Dimitrios Farmakis, Lorenz H. Lehmann, Johannes Backs, Christoph Maack, Carlo G. Tocchetti, Suma H Konety, Massimo F Piepoli, Thomas Thum, Radek Pudil, Oliver J. Müller, Daniel J. Lenihan, James Larkin, Alexander R. Lyon, Pierre Dodion, Thomas M. Suter, Pietro Ameri, Thomas Eschenhagen, Antoni Bayes-Genis, Jelena Čelutkienė, Stephan von Haehling, Peter P. Rainer, Andrew J.S. Coats, Piotr Ponikowski, Stefan D. Anker, Stephane Heymans

Publikováno v: European Journal of Heart Failure
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
European Journal of Heart Failure, 22(12), 2272-2289. Wiley
European journal of heart failure, Hoboken : Wiley, 2020, vol. 22, no. 12, p. 2272-2289
European Journal of Heart Failure, Oxford University Press (OUP), 2020, 22 (12), pp.2272-2289. ⟨10.1002/ejhf.2029⟩
European Journal of Heart Failure (2020)
European journal of heart failure, 22(12), 2272-2289. Wiley

The co‐occurrence of cancer and heart failure (HF) represents a significant clinical drawback as each disease interferes with the treatment of the other. In addition to shared risk factors, a growing body of experimental and clinical evidence revea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e893a7f12d37d932f973227cfb09e69
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4399

Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer

Autor: J. Renard, John F. Smyth, Michel Clavel, Jan B. Vermorken, Pierre Dodion, Stan B. Kaye, Stein Gundersen

Publikováno v: Annals of Oncology. 4:303-306

Summary Background The observed activity of cisplatin in breast cancer and its unattractive toxicity profile in palliative treatment warranted further study of platinum analogues in this disease. Patients and methods Sixty-two patients with recurrent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::835224db7186f84bb73945703b29b0d3
https://doi.org/10.1093/oxfordjournals.annonc.a058487

Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies

Autor: B. Winograd, H.E. Gall, W.W. ten Bokkel Huinink, G. Schwartsmann, W.J.F. van der Vijgh, H.M. Pinedo, Pierre Dodion, G. Simonetti, Jan B. Vermorken, J. Joggi, M.B. van Hennik, Nadine Crespeigne

Publikováno v: Cancer Chemotherapy and Pharmacology, 25, 345-351. Springer Verlag
Schwartsmann, G, Dodion, P, Vermorken, J B, ten Bokkel Huinink, W W, Joggi, J, Winograd, B, Gall, H, Simonetti, G, van der Vijgh, W J F, van Hennik, M B, Crespeigne, N & Pinedo, H M 1990, ' Phase I study of Brequinar sodium (NSC368390) in patients with solid malignancies ', Cancer Chemotherapy and Pharmacology, vol. 25, pp. 345-351 .

Brequinar sodium (DUP 785, NSC 368390) is a novel quinoline-carboxylic acid derivative that has been selected for clinical evaluation because of its broad spectrum of antitumor activity in animal models and its novel chemical structure. This compound

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c68e543633c1462decc1aa3082625b2
https://doi.org/10.1007/bf00686235

Clinical and Pharmacokinetic Studies on the New Platinum Complex Zeniplatin (CL286,558)

Autor: Nadine Crespeigne, Martine Piccart, Merrill J. Egorin, J. D. Kantrowitz, Pierre Dodion, R. Rastogi, Alan Forrest, Dominique de Valeriola

Publikováno v: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy ISBN: 9781489907400

In an effort to develop more active and less toxic analogues of cisplatin, zeniplatin (code number: CL 286,558; [2, 2-Bis (aminomethyl)-1, 3-propanediol-N,N′] [1, 1-cyclobutane dicarboxylato]-(2-) -0,0′] Platinum (Pt)) has been synthesized (Ameri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d3b341fd4dd616fbe57bf58819520434
https://doi.org/10.1007/978-1-4899-0738-7_33

Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma

Autor: G. Stoter, M. van Glabbeke, Franco Cavalli, Silvio Monfardini, W. W. ten Bokkel-Huinink, J. Renard, Stan B. Kaye, Stein Gundersen, J. Smith, Michel Clavel, Pierre Dodion, D. J. T. Wagener

Publikováno v: Investigational new drugs. 8

Phase II trials of flavone acetic acid have been performed in a total of 87 patients including 17 with advanced breast cancer, 23 with advanced colorectal cancer, 25 with advanced malignant melanoma and 22 with advanced head and neck cancer. Patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec483ae0b7fbe3d0b3bdc1574bd8baba
https://pubmed.ncbi.nlm.nih.gov/2380021